Phathom Pharmaceuticals, Inc. (PHAT) has a negative trailing P/E of -3.9, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 9.3 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -25.90%, forward earnings yield 10.80%. PEG 0.17 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
Overall SharesGrow Score: 54/100 with 2/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2018 | -163.8 | 0.00 | -164.09 | 0.00 | - |
| 2019 | -3.7 | 0.00 | 3.38 | 0.00 | - |
| 2020 | -8.6 | 0.16 | 5.68 | 0.00 | - |
| 2021 | -5.1 | 20.29 | 10.09 | 0.00 | - |
| 2022 | -2.2 | -0.05 | -5.87 | 0.00 | - |
| 2023 | -2.3 | 0.07 | -6.44 | 686.61 | - |
| 2024 | -1.5 | -0.04 | -2.02 | 9.28 | - |
| 2025 | -5.5 | 0.13 | -2.76 | 6.91 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2018 | $-0.15 | $0.00 | $-1.29M | - |
| 2019 | $-8.48 | $0.00 | $-209.74M | - |
| 2020 | $-4.01 | $0.00 | $-133.32M | - |
| 2021 | $-4.00 | $0.00 | $-148.09M | - |
| 2022 | $-5.70 | $0.00 | $-223.01M | - |
| 2023 | $-3.93 | $682K | $-201.59M | -29558.9% |
| 2024 | $-5.29 | $55.25M | $-334.33M | -605.1% |
| 2025 | $-3.03 | $175.11M | $-221.25M | -126.3% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-0.05 | $-0.06 – $-0.05 | $332.04M | $326.45M – $335.21M | 3 |
| 2027 | $1.34 | $1.28 – $1.42 | $528.17M | $512.75M – $551.73M | 4 |
| 2028 | $3.00 | $2.10 – $4.16 | $745.54M | $745.54M – $745.54M | 6 |
| 2029 | $4.13 | $3.92 – $4.35 | $891.63M | $857.14M – $929.34M | 4 |
| 2030 | $4.93 | $4.68 – $5.20 | $1.02B | $977.07M – $1.06B | 2 |
